|  |  |  |  |
| --- | --- | --- | --- |
| **Brand name** | **Eligible for DNP**  1= biosimilar (generic) available by 2023  2=not yet out of FDA approval window by 2023 | **If eligible, named in 2023 for DNP?** | **2021 total cost (2021 US dollars)** |
| Eliquis | Yes | Yes | $12,575,145,852 |
| Revlimid | No, 1 | -- | $5,893,547,772 |
| Xarelto | Yes | Yes | $5,225,547,772 |
| Trulicity | No, 2 | -- | $4,702,174,724 |
| Januvia | Yes | Yes | $4,059,534,112 |
| Jardiance | Yes | Yes | $3,735,773,560 |
| Imbruvica | Yes | Yes | $3,150,225,810 |
| Humira | No, 1 | -- | $2,907,332,478 |
| Lantus | No, 1 | -- | $2,831,447,261 |
| Ozempic | No, 2 | -- | $2,621,694,348 |
| Xtandi | No, 2 | -- | $2,411,262,130 |
| Trelegy | No, 2 | -- | $2,393,151,303 |
| Biktarvy | No, 2 | -- | $2,198,270,149 |
| Mirabegron | Yes | No | $1,989,099,248 |
| Symbicort | No, 1 | -- | $1,952,249,973 |
| Ibrance | No, 2 | -- | $1,891,416,132 |
| Novolog | Yes | Yes | $1,817,675,039 |
| Entresto | Yes | Yes | $1,722,714,576 |
| Restasis | No, 1 | -- | $1,628,418,856 |
| Pomelyst | No, 2 | -- | $1,595,079,245 |